MX2017003916A - Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. - Google Patents
Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.Info
- Publication number
- MX2017003916A MX2017003916A MX2017003916A MX2017003916A MX2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A MX 2017003916 A MX2017003916 A MX 2017003916A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- methylethyl
- cyclopentyl
- bis
- compositions
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 title 1
- SDOOGTHIDFZUNM-UHFFFAOYSA-N 1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(=CC=2)N(C)C)CCCC1 SDOOGTHIDFZUNM-UHFFFAOYSA-N 0.000 abstract 3
- 208000005676 Adrenogenital syndrome Diseases 0.000 abstract 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 abstract 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 abstract 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 abstract 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000001780 adrenocortical effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C07C273/1818—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from -N=C=O and XNR'R"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055964P | 2014-09-26 | 2014-09-26 | |
| US201462086153P | 2014-12-01 | 2014-12-01 | |
| PCT/US2015/052338 WO2016049518A1 (en) | 2014-09-26 | 2015-09-25 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003916A true MX2017003916A (es) | 2017-06-30 |
Family
ID=54291659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003916A MX2017003916A (es) | 2014-09-26 | 2015-09-25 | Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9546135B2 (enExample) |
| EP (1) | EP3197435A1 (enExample) |
| JP (1) | JP2017530132A (enExample) |
| CN (1) | CN107205941A (enExample) |
| AU (2) | AU2015320358B2 (enExample) |
| BR (1) | BR112017006287A2 (enExample) |
| CA (1) | CA2962597A1 (enExample) |
| MX (1) | MX2017003916A (enExample) |
| WO (1) | WO2016049518A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| WO2016164476A2 (en) * | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| CN112441941B (zh) * | 2020-12-03 | 2022-08-02 | 浙江荣耀生物科技股份有限公司 | 一种1-(4-氨基苯基)环戊基甲腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| JP2005068066A (ja) * | 2003-08-25 | 2005-03-17 | Air Water Chemical Inc | ２，６−ジイソプロピルアニリンの精製方法 |
| PE20170944A1 (es) * | 2010-03-23 | 2017-07-13 | Siga Tech Inc | Formas polimorficas de st-246 y metodos de preparacion |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| CN106236741A (zh) * | 2012-03-22 | 2016-12-21 | 密歇根大学董事会 | 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 |
-
2015
- 2015-09-25 US US14/866,212 patent/US9546135B2/en active Active
- 2015-09-25 WO PCT/US2015/052338 patent/WO2016049518A1/en not_active Ceased
- 2015-09-25 MX MX2017003916A patent/MX2017003916A/es unknown
- 2015-09-25 CN CN201580063601.XA patent/CN107205941A/zh active Pending
- 2015-09-25 BR BR112017006287A patent/BR112017006287A2/pt not_active Application Discontinuation
- 2015-09-25 EP EP15778492.7A patent/EP3197435A1/en not_active Withdrawn
- 2015-09-25 CA CA2962597A patent/CA2962597A1/en not_active Abandoned
- 2015-09-25 JP JP2017516764A patent/JP2017530132A/ja active Pending
- 2015-09-25 AU AU2015320358A patent/AU2015320358B2/en not_active Expired - Fee Related
-
2016
- 2016-12-06 US US15/370,980 patent/US10059660B2/en active Active
-
2019
- 2019-09-20 US US16/578,047 patent/US20200255372A1/en not_active Abandoned
-
2020
- 2020-04-27 AU AU2020202784A patent/AU2020202784A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/359,249 patent/US12151998B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12151998B2 (en) | 2024-11-26 |
| AU2015320358B2 (en) | 2020-05-14 |
| US9546135B2 (en) | 2017-01-17 |
| US20220162160A1 (en) | 2022-05-26 |
| AU2020202784A1 (en) | 2020-05-14 |
| US20160090354A1 (en) | 2016-03-31 |
| EP3197435A1 (en) | 2017-08-02 |
| US20200255372A1 (en) | 2020-08-13 |
| WO2016049518A1 (en) | 2016-03-31 |
| US10059660B2 (en) | 2018-08-28 |
| US20170305843A1 (en) | 2017-10-26 |
| JP2017530132A (ja) | 2017-10-12 |
| AU2015320358A1 (en) | 2017-05-11 |
| CA2962597A1 (en) | 2016-03-31 |
| BR112017006287A2 (pt) | 2017-12-12 |
| CN107205941A (zh) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| MX355129B (es) | Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| JOP20190174A1 (ar) | مثبطات jak1 انتقائية | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX2016001788A (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx. | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| UY34161A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen | |
| EP2782990A4 (en) | METHOD AND SYSTEMS FOR BREEDING PLANTS BY SILICATE-BASED SUBSTRATES, CULTURING WITH INCREASED PHOTOSYNTHETIC PRODUCTIVITY AND PHOTOSAFENING USING EXOGENOUS GLYCOPYRANOSIDES FOR ENDOGENIC GLYCOPYRANOSYL PROTEIN DERIVATIVES AND FORMULATIONS, METHODS AND SYSTEMS THEREFOR | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| PH12016502347A1 (en) | 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| CL2015000056A1 (es) | Compuestos derivados de carbamato/urea, inhibidores del receptor de histamina h3; procedimiento de preparación; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de narcolepsia. | |
| CN110382500A (zh) | 用于ido和tdo双重抑制剂的脲类化合物 | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| WO2014153495A3 (en) | Novel stat3 inhibitors | |
| HK1215190A1 (zh) | 载体连接型前列腺素类前药 | |
| UY34191A (es) | ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?. | |
| WO2014145314A3 (en) | Methods and compositions for gamma-glutamyl cycle modulation | |
| BR112017006287A2 (pt) | forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesma | |
| NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride |